Tandem Diabetes Care, Inc. (TNDM Quick QuoteTNDM - Free Report) reported a second-quarter 2026 loss of 31 cents per share, narrower than the Zacks Consensus Estimate of a loss of 34 cents. The figure improved from the year-ago loss of 78 cents. 

Worldwide revenues of $254.6 million rose 5.8% year over year and missed the consensus mark by 0.1%. Worldwide pump shipments exceeded 33,000, rising more than 10% year over year, while gross margin reached 57%.

Following the earnings announcement, TNDM shares gained 19.1% last Friday. 

TNDM's U.S. Sales Rise on Supplies Growth

U.S. revenues increased 5% year over year to $179.29 million. Pump revenues declined 3% to $83.00 million, while supplies and other revenues climbed 14% to $96.29 million. U.S. pump shipments exceeded 22,000 compared with approximately 21,000 a year ago.

Tandem's pay-as-you-go, or PAYGO, pharmacy model continued to gain traction. Pharmacy sales represented 10% of total U.S. sales in the quarter. Management said the initial revenue headwind from pumps sold through the pharmacy channel was approximately $8 million because those shipments carry no upfront pump reimbursement.

Tandem Diabetes Sees International Shipment Growth

International revenues rose 7% year over year to $75.27 million and increased 6% at constant currency. Pump sales advanced 20% to $31.65 million, while supplies and other sales slipped 1% to $43.62 million. International pump shipments totaled approximately 11,000, up from roughly 9,000.

Direct-channel sales accounted for about 13% of international revenues, more than double the year-ago level. Results included roughly $3 million of headwinds tied to distributor inventory buybacks and de-stocking ahead of direct-market transitions. Infusion-set supply constraints also limited distributor order fulfillment late in the quarter.

TNDM's Gross Margin Shows Strong Expansion

Gross profit increased to $144.78 million from $125.86 million a year earlier. Gross margin expanded 460 basis points year over year to 57%, reflecting favorable pricing from channel initiatives and product cost improvements as Tandem Mobi volumes scaled.

Operating expenses fell to $158.57 million from $177.67 million. Selling, general and administrative expenses rose to $111.64 million from $109.60 million, while research and development expenses declined to $46.93 million from $48.12 million. The operating loss narrowed to $13.79 million from $51.81 million.

Tandem Diabetes Care, Inc. Price, Consensus and EPS Surprise

Tandem Diabetes Care, Inc. price-consensus-eps-surprise-chart | Tandem Diabetes Care, Inc. Quote

TNDM Maintains 2026 Sales and Margin Outlook

TNDM reaffirmed its 2026 worldwide sales guidance of $1.065 billion to $1.085 billion. U.S. sales are projected between $730 million and $745 million, while international sales are expected to be in the $335-$340 million range. The Zacks Consensus Estimate for full-year revenues is pegged at $1.07 billion.

For the third quarter, management expects worldwide sales of approximately $265 million, comprising about $180 million in the United States and $85 million internationally. 

Tandem Diabetes Maintains a Solid Cash Position

Tandem ended the second quarter with $456.00 million in cash, cash equivalents and short-term investments compared with $570 million at the end of the first quarter. 

Cash used in operating activities totaled $34.62 million in the quarter compared with $9.50 million a year earlier. Capital expenditures amounted to $4.05 million, resulting in a negative free cash flow of $38.67 million compared with $15.70 million in the prior-year quarter.

Our Take

Tandem Diabetes incurred a narrower-than-expected quarterly loss but missed on revenues. Its performance benefited from higher pump shipments, favorable pharmacy-channel pricing and product cost improvements. A key milestone in the quarter was that the PAYGO formulary coverage reached approximately 45%, approaching the high end of Tandem's 2026 target range. Expansion of gross margin is highly promising. 

On a negative note, the company’s loss looks discouraging. 

TNDM’s Zacks Rank and Key Picks

Tandem Diabetes currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are Intuitive Surgical ISRG, Quest Diagnostics DGX and Medpace MEDP.

Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.80, which surpassed the Zacks Consensus Estimate by 12.9%. Revenues of $2.89 billion beat the Zacks Consensus Estimate by 3.1%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

ISRG has an earnings yield of 3.1% compared to the industry’s negative 3% yield. The company beat earnings estimates in each of the trailing four quarters, the average surprise being 16.53%.

Quest Diagnostics, carrying a Zacks Rank #2 at present, posted second-quarter 2026 adjusted EPS of $3.12, which outpaced the Zacks Consensus Estimate by 11%. Revenues of $3.04 billion topped the Zacks Consensus Estimate by 2.1%.

DGX has an earnings yield of 4.7%, almost in line with the industry’s yield. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 5.77%.

Medpace, carrying a Zacks Rank #2 at present, posted second-quarter 2026 adjusted EPS of $4.25, which beat the Zacks Consensus Estimate by 4.17%. Revenues of $707.3 million outperformed the consensus mark by 1.12%.

MEDP has a historical five-year earnings growth rate of 30.5% compared with the industry’s 5.6% growth. In the trailing four quarters, the company delivered an average earnings beat of 10.16%.